Skip to main content
OpenTrials
Completed

NCT Number: NCT00226564

Genetic Determinants of Opioids Analgesia

The response to opioids varies greatly among individuals. Some of these variability is accounted for by genetic factors.

The present study was designed to evaluate the possibility that genetic polymorphism in the gene encoding for mu opioid receptor may explain variability in the response to alfentanil during lithotripsy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hadassah Medical Organization

Jerusalem, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 20

Exclusion criteria

  • Regular use of opioid drugs
  • Known hypersensitivity to alfentanil

Treatment and study plan

alfentanil

Drug

Primary outcomes

  1. Total alfentanil dose used during the procedure.

  2. The extent of respiratory depression.

Sponsors and collaborators

Lead sponsor

Hadassah Medical Organization

Other

Registry information

Official study title

The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy

Important dates

Study start
1997
First posted
Sep 27, 2005
Registry last updated
Oct 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.